What the FDA labels say about taking them together
Atazanavir and fluticasone
Fluticasone's FDA label of December 19, 2024 names atazanavir in its drug interactions (prescription label) section; atazanavir's label does not name fluticasone itself but warns about its class (Corticosteroids). The fluticasone label: “The use of strong CYP3A4 inhibitors with Fluticasone Propionate DISKUS is not recommended because increased systemic corticosteroid adverse effects may occur.”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the fluticasone FDA label on DailyMed (effective December 19, 2024, Haleon US Holdings LLC).
What does the atazanavir label say about fluticasone?
Atazanavir's label does not name fluticasone itself; it warns about its class (Corticosteroids):
Atazanavir label, drug interactionsCorticosteroids: dexamethasone and other corticosteroids (all routes of administration) ↓ atazanavir ↑ corticosteroids Coadministration with dexamethasone or other corticosteroids that induce CYP3A may result in loss of therapeutic effect of atazanavir and development of resistance to atazanavir and/or ritonavir.
Atazanavir label, drug interactionsCoadministration with corticosteroids (all routes of administration) that are metabolized by CYP3A, particularly for long-term use, may increase the risk for development of systemic corticosteroid effects including Cushing’s syndrome and adrenal suppression.
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the fluticasone label say about atazanavir?
Fluticasone label, drug interactions (prescription label)The use of strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, conivaptan, lopinavir, voriconazole) with XHANCE is not recommended because increased systemic corticosteroid adverse effects may occur.
Fluticasone Propionate Diskus label (Sportpharm LLC, July 28, 2026), warnings and precautionsInteractions with Strong Cytochrome P450 3A4 Inhibitors The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with Fluticasone Propionate DISKUS is not recommended because increased systemic corticosteroid adverse effects may occur [see Drug Interactions ( 7.1 ), Clinical Pharmacology ( 12.3 )].
Source: FDA drug label (Fluticasone Propionate Diskus, NDA020833), Sportpharm LLC, effective July 28, 2026 (SPL set 348cbd8c-edeb-499c-961d-3aeb5cc2cef1), via openFDA
Source: FDA drug label (FLONASE ALLERGY RELIEF), Haleon US Holdings LLC, effective December 19, 2024 (SPL set b6134ba0-b70a-4eac-9a82-cef64b242c1d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Fluticasone | |
|---|---|---|
| Labeled for | HIV | Allergies, Asthma, Eczema (atopic dermatitis) |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | $0.243 per gram 0.05% cream |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once